Endo Pharmaceuticals has entered into a collaboration with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.
The partnership allows the companies to bring forward a total of eight “discovery phase” candidates.
The collaboration also allows both companies to exclusively license the others’ development-ready programs at pre-determined stages and share all development costs.
“This alliance marks another milestone in the transformation of Endo’s R&D platform,” said Dr. Ivan Gergel M.D., executive vice president, Research & Development at Endo Pharmaceuticals.
“We are excited about this opportunity to collaborate with an experienced partner like Orion and look forward to continuing to bring new therapies and healthcare solutions to payers, physicians and patients.
“This type of collaboration fits well into our new, efficient and effective virtual R&D model.”
Dr. Reijo Salonen, senior vice president of Orion Corporation’s Research and Development, commented: “I am very pleased with the collaboration agreement with Endo.
“This will immediately extend the Oncology R&D pipelines of both companies.
“We look forward to developing new cancer therapies for the patients jointly with Endo.”